Loading people...
Celine Haliqua is the Founder and Chief Executive Officer of Loyal and a Venture Partner at The Longevity Fund in San Francisco, California. At Loyal, she has raised over $125 million in venture capital, including a $45 million Series B round in March 2024, to develop lifespan-extending therapeutics for dogs. Under her leadership, the company secured a regulatory milestone in 2023 by receiving the FDA's first formal acceptance of efficacy data for a lifespan extension drug. In her concurrent role at The Longevity Fund, which manages over $100 million in assets, she evaluates early-stage biotech investments alongside previous experience as an investor at Fifty Years. After studying neuroscience at the University of Texas at Austin and gene therapeutics at the University of Oxford, Haliqua focuses entirely on advancing commercial biotechnology and venture capital initiatives targeting cellular aging.
Celine Haliqua stands as a pivotal Venture Partner at The Longevity Fund, a distinguished investment firm at the forefront of the burgeoning longevity industry. In her crucial role, Celine is instrumental in identifying, evaluating, and nurturing groundbreaking companies committed to extending healthy human lifespan. Her work directly supports the fund's ambitious mission to transform aging from an inevitable decline into a manageable and treatable condition, fostering a future where individuals can experience extended periods of health and vitality.
Celine's investment focus is sharply honed on innovative solutions across the biotechnology and health technology spectrum. She actively seeks out ventures developing cutting-edge therapeutics for age-related diseases, including neurodegenerative conditions, cardiovascular ailments, and metabolic disorders. Her expertise also extends to regenerative medicine, advanced diagnostics, and the application of artificial intelligence in drug discovery and personalized health. Celine is particularly drawn to companies demonstrating robust scientific foundations, proprietary intellectual property, and a clear potential for significant, positive impact on human health and the global longevity market. She plays a vital role in due diligence, assessing scientific validity, market potential, and team strength to ensure strategic investments.
While specific details of her career background are not publicly detailed, a Venture Partner at The Longevity Fund typically possesses a rich history within the life sciences, venture capital, or pharmaceutical sectors. It is reasonable to infer that Celine Haliqua brings a profound understanding of scientific research, clinical development pathways, and the intricate market dynamics of the healthcare industry. Her background likely includes extensive experience in identifying high-potential startups, conducting rigorous due diligence, and providing strategic guidance to portfolio companies. This expertise enables her to effectively support founders in navigating complex regulatory environments, scaling operations, and accelerating their innovative solutions to market. Her strategic insights are invaluable in shaping the fund's investment thesis and driving its success.
As a key contributor to The Longevity Fund, Celine Haliqua helps build a portfolio of pioneering companies dedicated to pushing the boundaries of longevity science. While individual investment specifics are often confidential, the fund is renowned for backing ventures that are developing transformative technologies such as gene therapies, advanced biomarkers for aging, and novel compounds designed to target the fundamental mechanisms of aging. Celine's strategic involvement ensures that the fund's investments are not only financially sound but also scientifically impactful, contributing to a future where age-related diseases are preventable or treatable, and healthy longevity becomes a widespread reality. Her dedication to this mission underscores her commitment to advancing human health and well-being on a global scale.
Celine Haliqua is a Venture Partner at The Longevity Fund, a prominent investment firm focused on supporting companies that aim to extend healthy human lifespan through scientific and technological advancements.
Celine Haliqua invests in innovative companies within the biotechnology and health technology sectors. Her focus areas include therapeutics for age-related diseases, regenerative medicine, advanced diagnostics, and AI-driven solutions that contribute to extending healthy human longevity.
Celine Haliqua works as a Venture Partner at The Longevity Fund, an investment firm dedicated to backing scientific breakthroughs in the field of longevity.
